MGX
Metagenomi Inc.

786
Mkt Cap
$56.7M
Volume
510,437.00
52W High
$4.92
52W Low
$1.23
PE Ratio
-0.63
MGX Fundamentals
Price
$1.51
Prev Close
$1.51
Open
$1.51
50D MA
$2.40
Beta
0.97
Avg. Volume
947,221.65
EPS (Annual)
-$2.09
P/B
0.32
Rev/Employee
$258,886.14
Loading...
Loading...
News
all
press releases
Metagenomi, Inc. (NASDAQ:MGX) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are presently covering the firm, MarketBeat Ratings...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Metagenomi (NASDAQ:MGX) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Metagenomi (NASDAQ:MGX - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of...
MarketBeat·9d ago
News Placeholder
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce
Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027.read more...
Benzinga·10d ago
News Placeholder
Metagenomi (MGX) Reports Q3 Loss, Lags Revenue Estimates
Metagenomi (MGX) delivered earnings and revenue surprises of +8.33% and -6.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates
KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of +4.17% and +242.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +19.68% and +10.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -7.69% and -4.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Here's Why Metagenomi (MGX) is a Great Momentum Stock to Buy
Does Metagenomi (MGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·1mo ago
News Placeholder
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
Metagenomi (MGX) delivered earnings and revenue surprises of +20.59% and +20.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of +42.86% and +53.76%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago

Latest MGX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.